Loading company…
Lyon-based Osivax SAS develops universal vaccines against highly mutating viruses, with its lead candidate OVX836 in clinical trials.
Founded in 2017 and headquartered in Lyon, France, Osivax SAS develops universal vaccines based on its oligoDOM technology, which uses self-assembling nanoparticles to target conserved internal viral antigens. Its lead candidate, OVX836, has completed Phase 1 and Phase 2a trials, and the company is also working on other infectious diseases beyond influenza and coronaviruses. In March 2025 it raised EUR 10 million in Series B funding. Alexandre Le Vert founded the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in